Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Celldex Therapeutics (CLDX) Thoughts on EAACI and Phase 1b Barzolvolimab CSU Data - Cantor Fitzgerald
-
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Celldex (CLDX) Prices Upsized 5.95M Share Offering at $42/sh
-
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock
-
Celldex (CLDX) Announces up to $175M Share Offering
-
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
-
Celldex Therapeutics (CLDX) PT Raised to $61 at Cantor Fitzgerald
-
Pre-Open Stock Movers 03/30: (MBRX) (ABCL) (SEEL) Higher; (WVE) (BFLY) (CLDX) Lower (more...)
-
After-Hours Stock Movers 03/29: (BIOC) (SEAC) (NOVN) Higher; (WVE) (BFLY) (CLDX) Lower (more...)
-
Celldex Therapeutics (CLDX) PT Raised to $35 at Cantor Fitzgerald
-
Celldex Therapeutics (CLDX) PT Raised to $22 at Cantor Fitzgerald
-
Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Pre-Open Stock Movers 06/16: (IDYA) (IQ) (HEAR) Higher; (IZEA) (CLDX) (CHK) Lower (more...)
-
Celldex (CLDX) Prices 13.378M Share Common Offering at $9.75/Sh
-
Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock
-
After-Hours Stock Movers 06/15: (WW) (MBIO) (VRAY) Higher; (CLDX) (AVEO) (AAXN) Lower (more...)
-
Celldex (CLDX) Announces Proposed Common Share Offering
-
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
-
Celldex Therapeutics (CLDX) PT Raised to $12 at Cantor Fitzgerald After Positive CDX-0159 Data
-
Pre-Open Stock Movers 02/21: (BXRX) (CRC) (DBX) Higher (TRUE) (BXC) (EYPT) Lower (more...)
-
After-Hours Stock Movers 02/20: (ZIXI) (EHTH) (DBX) Higher (EYPT) (TRUE) (FSLR) Lower (more...)
-
Cantor Fitzgerald Starts Celldex Therapeutics (CLDX) at Overweight
-
UPDATE: Cantor Fitzgerald Downgrades Celldex Therapeutics (CLDX) to Neutral, 'Glemba in Rear View Mirror'
-
Celldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Pre-Open Stock Movers 03/15: (PIP) (ARNA) (MSCI) Higher; (RUBI) (NPTN) (NMM) Lower (more...)
-
After-Hours Stock Movers 03/14: (PIP) (ARNA) (RST) Higher; (RUBI) (NPTN) (FTD) Lower (more...)
-
Celldex Reports Second Quarter 2016 Results
-
Celldex Therapeutics to Participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference
-
Celldex (CLDX) Enters Controlled Equity Sales Agreement
-
Cantor Fitzgerald Cuts Price Target on Celldex (CLDX) to $31 Following Rintega Filing Delay
-
Celldex Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
-
Celldex Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
-
Celldex (CLDX) Bullish Stance Reiterated at Cantor Fitzgerald Following Q1 and Update
-
Celldex Therapeutics (CLDX) PT Raised to $38 at Cantor Fitzgerald; 2015 Shaping Up to Be Strong
-
Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares
-
Celldex Therapeutics Prices Public Offering of Common Stock
-
Celldex Therapeutics (CLDX) Target Raised to $39 at Cantor
-
Cantor Fitzgerald's Conviction Calls For 2013
-
Cantor Fitzgerald Starts Celldex Therapeutics (CLDX) at Buy; Valuation Not Reflecting Depth
-
Celldex (CLDX) Enters Debt and Equity Financing Facilities

